Pilar Alfonso

4.5k total citations
115 papers, 1.7k citations indexed

About

Pilar Alfonso is a scholar working on Oncology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pilar Alfonso has authored 115 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 38 papers in Physiology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pilar Alfonso's work include Colorectal Cancer Treatments and Studies (52 papers), Lysosomal Storage Disorders Research (38 papers) and Cancer Treatment and Pharmacology (23 papers). Pilar Alfonso is often cited by papers focused on Colorectal Cancer Treatments and Studies (52 papers), Lysosomal Storage Disorders Research (38 papers) and Cancer Treatment and Pharmacology (23 papers). Pilar Alfonso collaborates with scholars based in Spain, United States and France. Pilar Alfonso's co-authors include Pilar Giraldo, Miguel Pocovı́, Pilar Irún, S. Lasserre, John Bridgewater, Ian Chau, René Adam, Thomas Gruenberger, Daniel Waterkamp and Michel Rivoire and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Pilar Alfonso

108 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pilar Alfonso Spain	22	728	641	435	364	328	115	1.7k
Juan A. Recio Spain	23	61 0.1×	526 0.8×	1.0k 2.3×	253 0.7×	30 0.1×	53	1.8k
Akinobu Yoshimura Japan	22	112 0.2×	553 0.9×	704 1.6×	135 0.4×	50 0.2×	69	1.5k
Benedetta Peruzzi Italy	18	78 0.1×	233 0.4×	612 1.4×	67 0.2×	58 0.2×	38	1.2k
Hisatsugu Goto Japan	26	131 0.2×	558 0.9×	554 1.3×	35 0.1×	36 0.1×	74	1.6k
Masashi Haraguchi Japan	17	108 0.1×	189 0.3×	515 1.2×	135 0.4×	60 0.2×	40	1.1k
Elba A. Turbat‐Herrera United States	22	84 0.1×	308 0.5×	735 1.7×	79 0.2×	62 0.2×	80	1.5k
David R. Gandara United States	24	59 0.1×	834 1.3×	573 1.3×	53 0.1×	43 0.1×	47	1.6k
Özgül Sağol Türkiye	20	58 0.1×	461 0.7×	325 0.7×	93 0.3×	19 0.1×	102	1.2k
Margret Rave‐Fränk Germany	25	80 0.1×	665 1.0×	732 1.7×	63 0.2×	17 0.1×	89	1.9k
Avi I. Einzig United States	20	94 0.1×	1.2k 1.9×	382 0.9×	169 0.5×	45 0.1×	34	1.7k

Countries citing papers authored by Pilar Alfonso

Since Specialization

Citations

This map shows the geographic impact of Pilar Alfonso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pilar Alfonso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pilar Alfonso more than expected).

Fields of papers citing papers by Pilar Alfonso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pilar Alfonso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pilar Alfonso. The network helps show where Pilar Alfonso may publish in the future.

Co-authorship network of co-authors of Pilar Alfonso

This figure shows the co-authorship network connecting the top 25 collaborators of Pilar Alfonso. A scholar is included among the top collaborators of Pilar Alfonso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pilar Alfonso. Pilar Alfonso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elez, Élena, Antonio Cubillo, Pilar Alfonso, et al.. (2024). Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. BMC Cancer. 24(1). 446–446. 2 indexed citations

Alfonso, Pilar, David Páez, Ana Fernández Montés, et al.. (2023). 560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial. Annals of Oncology. 34. S416–S417. 1 indexed citations

Frutos, Laura López de, Pilar Alfonso, Carlos Lahoz, Pilar Irún, & Pilar Giraldo. (2020). Allelic and phenotypic characterization of CYP2D6 and its encoded P450 cytochrome enzyme in a serie of Spanish type 1 Gaucher disease patients. Medicina Clínica. 155(12). 529–534. 1 indexed citations

Beveridge, Robert Díaz, Ana Fernández Montés, Julia Alcaide, et al.. (2019). Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients. Annals of Oncology. 30. iv51–iv52. 1 indexed citations

Viéitez, José María, Silvia Gil, Begoña Graña, et al.. (2018). Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).. Journal of Clinical Oncology. 36(15_suppl). 3536–3536. 2 indexed citations

Overman, Michael J., Sara Lonardi, Francesco Leone, et al.. (2017). Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. Journal of Clinical Oncology. 35(4_suppl). 519–519. 58 indexed citations

Carmona‐Bayonas, Alberto, Andrés J. Muñoz Martín, Luisa Sánchez‐Lorenzo, et al.. (2016). First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry. Annals of Oncology. 27. vi212–vi212. 3 indexed citations

Marques, André R. A., Jan Aten, Cindy P. A. A. van Roomen, et al.. (2016). Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease. PLoS ONE. 11(1). e0147208–e0147208. 49 indexed citations

Carrato, Alfredo, Manuel Benavides, Carmen Guillén‐Ponce, et al.. (2015). Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. Journal of Clinical Oncology. 33(15_suppl). e14524–e14524. 1 indexed citations

10.

Vera, Ruth, María Luisa Gómez Dorronsoro, Juan Ramón Ayuso, et al.. (2015). Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.. Journal of Clinical Oncology. 33(15_suppl). e14656–e14656. 1 indexed citations

11.

Alfonso, Pilar, Vanesa Andreu, Almudena Pino‐Ángeles, et al.. (2013). Bicyclic Derivatives of L‐Idonojirimycin as Pharmacological Chaperones for Neuronopathic Forms of Gaucher Disease. ChemBioChem. 14(8). 943–949. 32 indexed citations

12.

Adam, René, John Bridgewater, Ian Chau, et al.. (2013). Randomised, Phase 2 Study (OLIVIA) of Bevacizumab Plus mFOLFOX6 or Folfoxiri in Patients with Initially Unresectable Colorectal Cancer Liver Metastases. Annals of Oncology. 24. iv21–iv21. 3 indexed citations

13.

Irún, Pilar, et al.. (2013). Analysis of efficacy and safety of two iron chelators in type 1 Gaucher disease patients with iron overload. Molecular Genetics and Metabolism. 108(2). S64–S65. 1 indexed citations

14.

Rivera, Fernando, Pilar Alfonso, Carlos López, et al.. (2013). NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis.. Journal of Clinical Oncology. 31(15_suppl). 4098–4098. 13 indexed citations

15.

Giraldo, Pilar, Pilar Alfonso, Pilar Irún, et al.. (2012). Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Orphanet Journal of Rare Diseases. 7(1). 17–17. 43 indexed citations

16.

Alfonso, Pilar, et al.. (2011). Cáncer colorrectal en el anciano. 25(2). 78–90.

17.

García‐Carbonero, Rocio, Vicente Alonso Orduña, Andrés Cervantes, et al.. (2010). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clinical & Translational Oncology. 12(11). 729–734. 10 indexed citations

18.

Giraldo, Pilar, Pilar Alfonso, Abelardo Bárez, et al.. (2009). Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 94(12). 1771–1775. 54 indexed citations

19.

Alfonso, Pilar, Juan Ignacio Pérez‐Calvo, Ana Cenarro, et al.. (2002). High Prevalence of the 55-bp Deletion (c.1263del55) in Exon 9 of the Glucocerebrosidase Gene Causing Misdiagnosis (for Homozygous N370S (c.1226A > G) Mutation) in Spanish Gaucher Disease Patients. Blood Cells Molecules and Diseases. 29(1). 35–40. 12 indexed citations

20.

Calvo, Felipe A., M. Gómez-Espí, Juan A. Díaz-González, et al.. (2001). Pathologic downstaging of T3–4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur. International Journal of Radiation Oncology*Biology*Physics. 51(5). 1264–1270. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact